The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search feed instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content
| Childers, Schlueter & Smith

The Food and Drug Administration recently rejected approval of Cephalon Inc.’s newest drug Sparlon, an attention deficit/hyperactivity disorder drug, after it was found to trigger Stevens-Johnson Syndrome (SJS), a serve allergic reaction that often times is fatal. The debilitating drug induced reaction kills thousands of consumers each year and was determined to be too great a risk for the public at large. Finally, the FDA is taking a firm stand on new drugs related to and triggering SJS. Now if they would help facilitate the removal of other dangerous drugs connected to SJS already on the market we all would be a lot safer when it comes to dealing with this tragic allergic reaction.

Comments are closed.